Cargando…

Importance of Occupational Exposure Data: A National Idiopathic Pulmonary Fibrosis Registry Perspective

Detalles Bibliográficos
Autores principales:	Teoh, Alan K. Y., Glaspole, Ian, Macansh, Sacha, Corte, Tamera J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193850/ https://www.ncbi.nlm.nih.gov/pubmed/31940213 http://dx.doi.org/10.1164/rccm.201911-2242LE

Ejemplares similares

Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry
por: Jo, Helen E., et al.
Publicado: (2018)

Collecting Occupational Exposure Data Would Strengthen Idiopathic Pulmonary Fibrosis Registries
por: Nett, Randall J., et al.
Publicado: (2020)

Reply to Nett et al.: Collecting Occupational Exposure Data Would Strengthen Idiopathic Pulmonary Fibrosis Registries
por: Culver, Daniel A., et al.
Publicado: (2020)

The economic burden of idiopathic pulmonary fibrosis in Australia: a cost of illness study
por: Cox, Ingrid A., et al.
Publicado: (2022)

Assessment of health-related quality of life in Australian patients with idiopathic pulmonary fibrosis: a comparison of the EQ-5D-5L and the AQoL-8D
por: Cox, Ingrid A., et al.
Publicado: (2022)

Patient Registries in Idiopathic Pulmonary Fibrosis
por: Culver, Daniel A., et al.
Publicado: (2019)

Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry
por: Jo, Helen E., et al.
Publicado: (2019)

Health-related quality of life of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis
por: Cox, Ingrid A., et al.
Publicado: (2020)

Australasian interstitial lung disease registry (AILDR): objectives, design and rationale of a bi-national prospective database
por: Moore, Irene, et al.
Publicado: (2020)

Patient Registries in Idiopathic Pulmonary Fibrosis: Don't Forget Socioeconomic Status
por: Sesé, Lucile, et al.
Publicado: (2020)

Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta-analysis
por: Zheng, Qiang, et al.
Publicado: (2022)

Quantitative computed tomography predicts outcomes in idiopathic pulmonary fibrosis
por: Humphries, Stephen M., et al.
Publicado: (2022)

Comment on Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults
por: Scholand, Mary Beth, et al.
Publicado: (2022)

Occupational Benzene Exposure and Lymphoma Risks
por: Sorahan, Tom
Publicado: (2011)

Postvaccination Acute Exacerbations of Idiopathic Pulmonary Fibrosis?
por: Huang, Jin-Xian, et al.
Publicado: (2022)

The supportive care needs of people living with pulmonary fibrosis and their caregivers: a systematic review
por: Lee, Joanna Y.T., et al.
Publicado: (2020)

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
por: Corte, Tamera, et al.
Publicado: (2015)

When is cystic fibrosis not cystic fibrosis? The importance of appropriately classifying patients
por: Faro, Albert, et al.
Publicado: (2022)

Overlooked Role of Histopathology in Evaluations for Occupational/Environmental Exposures
por: Sanyal, Soma, et al.
Publicado: (2020)

Comparing Transbronchial Cryobiopsy and Surgical Biopsy in Idiopathic Pulmonary Fibrosis
por: Quadrelli, Silvia, et al.
Publicado: (2019)

Comments on COVID-19 Vaccination and Exacerbation of Idiopathic Pulmonary Fibrosis
por: Kang, Tianlun, et al.
Publicado: (2022)

COVID-19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary Fibrosis
por: Sgalla, Giacomo, et al.
Publicado: (2022)

U.S. Occupational Historical Perspective on Race and Lung Function
por: Townsend, Mary C., et al.
Publicado: (2022)

Evaluating the interstitial lung disease multidisciplinary meeting: a survey of expert centres
por: Jo, Helen E., et al.
Publicado: (2016)

Too Premature to Deny the Potential of Thrombomodulin Alfa in Idiopathic Pulmonary Fibrosis
por: Kobayashi, Tetsu, et al.
Publicado: (2020)

Measurement of hypoxia in the lung in idiopathic pulmonary fibrosis: a matter of control
por: Bellaye, Pierre-Simon, et al.
Publicado: (2022)

Idiopathic Pulmonary Fibrosis Update: Reconciliation with Hypersensitivity Pneumonitis Guidelines Required?
por: Moran-Mendoza, Onofre
Publicado: (2022)

Antifibrotics and Reduced Mortality in Idiopathic Pulmonary Fibrosis: Immortal Time Bias
por: Suissa, Samy, et al.
Publicado: (2022)

CXCR4(+) cells are increased in lung tissue of patients with idiopathic pulmonary fibrosis
por: Jaffar, Jade, et al.
Publicado: (2020)

Thrombomodulin Did Not Benefit Acute Exacerbation of Idiopathic Pulmonary Fibrosis in a Trial
por: Horita, Nobuyuki, et al.
Publicado: (2020)

Identification of autophagy-related genes in idiopathic pulmonary fibrosis using bioinformatics methods
por: Sun, Shulei, et al.
Publicado: (2022)

Reply: Measurement of hypoxia in the lung in idiopathic pulmonary fibrosis: a matter of control
por: Porter, Joanna C., et al.
Publicado: (2022)

Hematopoietic and Lung Platelet Biogenesis as a Prognostic Indicator in Idiopathic Pulmonary Fibrosis
por: Saito, Shigeki, et al.
Publicado: (2022)

Occupational Benzene Exposure and Lymphoma Risks: Vlaanderen et al. Respond
por: Vlaanderen, Jelle, et al.
Publicado: (2011)

Linkage of the UK Clinical Practice Research Datalink with the national cancer registry
por: Badrick, Ellena, et al.
Publicado: (2018)

Demographic and clinical profile of idiopathic pulmonary fibrosis patients in Spain: the SEPAR National Registry
por: Fernández-Fabrellas, Estrella, et al.
Publicado: (2019)

There is detectable variation in the lipidomic profile between stable and progressive patients with idiopathic pulmonary fibrosis (IPF)
por: Nambiar, Shabarinath, et al.
Publicado: (2021)

Idiopathic pulmonary fibrosis and occupational risk factors
por: Ranzieri, Silvia, et al.
Publicado: (2019)

Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities
por: Glaspole, Ian, et al.
Publicado: (2021)

No increased prevalence of autoantibodies neutralizing type I IFNs in idiopathic pulmonary fibrosis patients
por: Philippot, Quentin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_317p7ij7hv48gkp1ll5ilpmsj0